A comprehensive overview of investigational elastase inhibitors for the treatment of acute respiratory distress syndrome

References

• Definition Task Force ARDS, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526–2533.
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Bianco A, et al. Pharmacological management of adult patients with acute respiratory distress syndrome. Expert Opin Pharmacother. 2020;21(17):2169–2183. doi: 10.1080/14656566.2020.1801636
   PubMed Web of Science ®Google Scholar
• Pham T, Rubenfeld GD. Fifty years of research in ARDS. The epidemiology of acute respiratory distress syndrome. A 50th birthday review. Am J Respir Crit Care Med. 2017;195(7):860–870. doi: 10.1164/rccm.201609-1773CP
   PubMed Web of Science ®Google Scholar
• Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685–1693. doi: 10.1056/NEJMoa050333
   PubMed Web of Science ®Google Scholar
• Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800. doi: 10.1001/jama.2016.0291
   PubMed Web of Science ®Google Scholar
• Caser EB, Zandonade E, Pereira E, et al. Impact of distinct definitions of acute lung injury on its incidence and outcomes in Brazilian ICUs: prospective evaluation of 7,133 patients*. Crit Care Med. 2014;42(3):574–582. doi: 10.1097/01.ccm.0000435676.68435.56
   PubMed Web of Science ®Google Scholar
• Manzano F, Yuste E, Colmenero M, et al. Incidence of acute respiratory distress syndrome and its relation to age. J Crit Care. 2005;20(3):274–280. doi: 10.1016/j.jcrc.2005.05.008
   PubMed Web of Science ®Google Scholar
• Hendrickson KW, Peltan ID, Brown SM. The epidemiology of acute respiratory distress syndrome before and after coronavirus disease 2019. Crit Care Clin. 2021;37(4):703–716. doi: 10.1016/j.ccc.2021.05.001
   PubMed Web of Science ®Google Scholar
• Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. Lancet. 2021;398(10300):622–637. doi: 10.1016/S0140-6736(21)00439-6
   PubMed Web of Science ®Google Scholar
• Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18. doi: 10.1038/s41572-019-0069-0
   PubMed Web of Science ®Google Scholar
• Tisoncik JR, Korth MJ, Simmons CP, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16–32. doi: 10.1128/MMBR.05015-11
   PubMed Web of Science ®Google Scholar
• Potey PM, Rossi AG, Lucas CD, et al. Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential. J Pathol. 2019;247(5):672–685. doi: 10.1002/path.5221
   PubMed Web of Science ®Google Scholar
• Kambas K, Markiewski MM, Pneumatikos IA, et al. C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J Immunol. 2008;180(11):7368–7375. doi: 10.4049/jimmunol.180.11.7368
   PubMed Web of Science ®Google Scholar
• Caudrillier A, Kessenbrock K, Gilliss BM, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest. 2012;122(7):2661–2671. doi: 10.1172/JCI61303
   PubMed Web of Science ®Google Scholar
• Lefrançais E, Mallavia B, Zhuo H, et al. Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury. JCI Insight. 2018;3(3):e98178. doi: 10.1172/jci.insight.98178
   PubMed Web of Science ®Google Scholar
• Dries DJ. Acute respiratory distress syndrome and lung protection. Air Med J. 2016;35(2):59–62. doi: 10.1016/j.amj.2015.12.011
   PubMedGoogle Scholar
• Thompson BT, Chambers RC, Liu KD, et al. Acute respiratory distress syndrome. N Engl J Med. 2017;377(6):562–572. doi: 10.1056/NEJMra1608077
   PubMed Web of Science ®Google Scholar
• Bastarache JA, Wang L, Geiser T, et al. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax. 2007;62(7):608–616. doi: 10.1136/thx.2006.063305
   PubMed Web of Science ®Google Scholar
• Wright TK, Gibson PG, Simpson JL, et al. Neutrophil extracellular traps are associated with inflammation in chronic airway disease. Respirology. 2016;21(3):467–475. doi: 10.1111/resp.12730
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–1535. doi: 10.1126/science.1092385
   PubMed Web of Science ®Google Scholar
• Zemans RL, Matthay MA. What drives neutrophils to the alveoli in ARDS? Thorax. 2017;72(1):1–3. doi: 10.1136/thoraxjnl-2016-209170
   PubMed Web of Science ®Google Scholar
• Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis. 2011;6:413–421. doi: 10.2147/COPD.S10770
   PubMed Web of Science ®Google Scholar
• Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol. 2006;6(7):541–550. doi: 10.1038/nri1841
   PubMed Web of Science ®Google Scholar
• Zeng W, Song Y, Wang R, et al. Neutrophil elastase: from mechanisms to therapeutic potential. J Pharm Anal. 2023;13(4):355–366. doi: 10.1016/j.jpha.2022.12.003
   PubMed Web of Science ®Google Scholar
• Metzler KD, Goosmann C, Lubojemska A, et al. A myeloperoxidase-containing complex regulates neutrophil elastase release and actin dynamics during NETosis. Cell Rep. 2014;8(3):883–896. doi: 10.1016/j.celrep.2014.06.044
   PubMed Web of Science ®Google Scholar
• Belaaouaj A, McCarthy R, Baumann M, et al. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med. 1998;4(5):615–618. doi: 10.1038/nm0598-615
   PubMed Web of Science ®Google Scholar
• Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in acute lung injury. Eur J Pharmacol. 2002;451(1):1–10. doi: 10.1016/S0014-2999(02)02182-9
   PubMed Web of Science ®Google Scholar
• Sandhaus RA, Turino G. Neutrophil elastase-mediated lung disease. COPD. 2013;10 (Suppl 1):60–63. doi: 10.3109/15412555.2013.764403
   PubMedGoogle Scholar
• Ding Q, Wang Y, Yang C, et al. Clinical utility of the sivelestat for the treatment of ALI/ARDS: moving on in the controversy? Intensive Care Res. 2023;3(1):12–17. doi: 10.1007/s44231-022-00012-5
   PubMedGoogle Scholar
• Ham J, Kim J, Ko YG, et al. The dynamic contribution of neutrophils in the chronic respiratory diseases. Allergy Asthma Immunol Res. 2022;14(4):361–378. doi: 10.4168/aair.2022.14.4.361
   PubMed Web of Science ®Google Scholar
• Owen CA, Campbell EJ. The cell biology of leukocyte-mediated proteolysis. J Leukocyte Biol. 1999;65(2):137–150. doi: 10.1002/jlb.65.2.137
   PubMed Web of Science ®Google Scholar
• Lucas SD, Costa E, Guedes RC, et al. Targeting COPD: advances on low-molecular-weight inhibitors of human neutrophil elastase. Med Res Rev. 2013;33(Suppl 1):E73–E101. doi: 10.1002/med.20247
   PubMedGoogle Scholar
• Polverino E, Rosales-Mayor E, Dale GE, et al. The role of neutrophil elastase inhibitors in lung diseases. Chest. 2017;152(2):249–262. doi: 10.1016/j.chest.2017.03.056
   PubMed Web of Science ®Google Scholar
• Ma Y, Yang X, Chatterjee V, et al. Role of neutrophil extracellular traps and vesicles in regulating vascular endothelial permeability. Front Immunol. 2019;10:1037. doi: 10.3389/fimmu.2019.01037
   PubMed Web of Science ®Google Scholar
• Clancy DM, Sullivan GP, Moran HBT, et al. Extracellular neutrophil proteases are efficient regulators of IL-1, IL-33, and IL-36 cytokine activity but poor effectors of microbial killing. Cell Rep. 2018;22(11):2937–2950. doi: 10.1016/j.celrep.2018.02.062
   PubMed Web of Science ®Google Scholar
• Voynow JA, Shinbashi M. Neutrophil elastase and chronic lung disease. Biomolecules. 2021;11(8):1065. doi: 10.3390/biom11081065
   PubMed Web of Science ®Google Scholar
• Suzuki K, Okada H, Takemura G, et al. Neutrophil elastase damages the pulmonary endothelial glycocalyx in lipopolysaccharide-induced experimental endotoxemia. Am J Pathol. 2019;189(8):1526–1535. doi: 10.1016/j.ajpath.2019.05.002
   PubMed Web of Science ®Google Scholar
• Kodama T, Yukioka H, Kato T, et al. Neutrophil elastase as a predicting factor for development of acute lung injury. Intern Med. 2007;46(11):699–704. doi: 10.2169/internalmedicine.46.6182
   PubMed Web of Science ®Google Scholar
• McGuire WW, Spragg RG, Cohen AB, et al. Studies on the pathogenesis of the adult respiratory distress syndrome. J Clin Invest. 1982;69(3):543–553. doi: 10.1172/JCI110480
   PubMed Web of Science ®Google Scholar
• Cazzola M, Hanania NA, Page CP, et al. Novel anti-inflammatory approaches to COPD. Int J Chron Obstruct Pulmon Dis. 2023;18:1333–1352. doi: 10.2147/COPD.S419056
   PubMed Web of Science ®Google Scholar
• Pott GB, Beard KS, Bryan CL, et al. Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells. Front Public Health. 2013;1:19. doi: 10.3389/fpubh.2013.00019
   PubMedGoogle Scholar
• Chapman KR, Burdon JG, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360–368. doi: 10.1016/S0140-6736(15)60860-1
   PubMed Web of Science ®Google Scholar
• von Nussbaum F, Li VM. Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: into clinical testing with pre-adaptive pharmacophores. Bioorg Med Chem Lett. 2015;25(20):4370–4381. doi: 10.1016/j.bmcl.2015.08.049
   PubMed Web of Science ®Google Scholar
• Sallenave JM. Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity. Am J Respir Cell Mol Biol. 2010;42(6):635–643. doi: 10.1165/rcmb.2010-0095RT
   PubMed Web of Science ®Google Scholar
• Chotirmall SH, Al-Alawi M, McEnery T, et al. Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes. Ther Clin Risk Manag. 2015;11:143–151. doi: 10.2147/TCRM.S51474
   PubMed Web of Science ®Google Scholar
• Owen CA, Campbell MA, Sannes PL, et al. Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Bio. 1995;131(3):775–789. doi: 10.1083/jcb.131.3.775
   PubMed Web of Science ®Google Scholar
• Voynow JA, Zheng S, Kummarapurugu AB. Glycosaminoglycans as multifunctional anti-elastase and anti-inflammatory drugs in cystic fibrosis lung disease. Front Pharmacol. 2020;11:1011. doi: 10.3389/fphar.2020.01011
   PubMed Web of Science ®Google Scholar
• Shute JK. Heparin, low molecular weight heparin, and non-anticoagulant derivatives for the treatment of inflammatory lung disease. Pharmaceuticals (Basel). 2023;16(4):584. doi: 10.3390/ph16040584
   PubMedGoogle Scholar
• Kummarapurugu AB, Afosah DK, Sankaranarayanan NV, et al. Molecular principles for heparin oligosaccharide-based inhibition of neutrophil elastase in cystic fibrosis. J Biol Chem. 2018;293(32):12480–12490. doi: 10.1074/jbc.RA118.002644
   PubMed Web of Science ®Google Scholar
• Morla S, Sankaranarayanan NV, Afosah DK, et al. On the process of discovering leads that target the heparin-binding site of neutrophil elastase in the sputum of cystic fibrosis patients. J Med Chem. 2019;62(11):5501–5511. doi: 10.1021/acs.jmedchem.9b00379
   PubMed Web of Science ®Google Scholar
• Crocetti L, Quinn MT, Schepetkin IA, et al. A patenting perspective on human neutrophil elastase (HNE) inhibitors (2014-2018) and their therapeutic applications. Expert Opin Ther Pat. 2019;29(7):555–578. doi: 10.1080/13543776.2019.1630379
   PubMed Web of Science ®Google Scholar
• Ohbayashi H. Current synthetic inhibitors of human neutrophil elastase in 2005. Expert Opin Ther Pat. 2005;15(7):759–771. doi: 10.1517/13543776.15.7.759
   Web of Science ®Google Scholar
• Dahl R, Titlestad I, Lindqvist A, et al. Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial. Pulm Pharmacol Ther. 2012;25(2):169–177. doi: 10.1016/j.pupt.2011.12.011
   PubMed Web of Science ®Google Scholar
• Watz H, Nagelschmitz J, Kirsten A, et al. Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: a randomized controlled trial. Pulm Pharmacol Ther. 2019;56:86–93. doi: 10.1016/j.pupt.2019.03.009
   PubMed Web of Science ®Google Scholar
• Barth P, Bruijnzeel P, Wach A, et al. Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis. J Cyst Fibros. 2020;19(2):299–304. doi: 10.1016/j.jcf.2019.08.020
   PubMed Web of Science ®Google Scholar
• Honoré S, Attalah HL, Azoulay E, et al. Beneficial effect of an inhibitor of leukocyte elastase (EPI-hNE-4) in presence of repeated lung injuries. Shock. 2004;22(2):131–136. doi: 10.1097/01.shk.0000126861.77543.d0
   PubMed Web of Science ®Google Scholar
• Delacourt C, Hérigault S, Delclaux C, et al. Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am J Respir Cell Mol Biol. 2002;26(3):290–297. doi: 10.1165/ajrcmb.26.3.4611
   PubMed Web of Science ®Google Scholar
• Takayama M, Ishibashi M, Ishii H, et al. Effects of neutrophil elastase inhibitor (ONO-5046) on lung injury after intestinal ischemia-reperfusion. J Appl Physiol (1985). 2001;91(4):1800–1807. doi: 10.1152/jappl.2001.91.4.1800
   PubMed Web of Science ®Google Scholar
• Inoue Y, Seiyama A, Tanaka H, et al. Protective effects of a selective neutrophil elastase inhibitor (sivelestat) on lipopolysaccharide-induced acute dysfunction of the pulmonary microcirculation. Crit Care Med. 2005;33(8):1814–1822. doi: 10.1097/01.CCM.0000172547.54086.AD
   PubMed Web of Science ®Google Scholar
• Zhang H, Zeng J, Li J, et al. Sivelestat sodium attenuates acute lung injury by inhibiting JNK/NF-κB and activating Nrf2/HO-1 signaling pathways. Biomol Biomed. 2023;23(3):457–470. doi: 10.17305/bb.2022.8549
   PubMedGoogle Scholar
• Yang T, Zhang J, Sun L, et al. Combined effects of a neutrophil elastase inhibitor (sivelestat sodium) and a free radical scavenger (edaravone) on lipopolysaccharide-induced acute lung injury in rats. Inflamm Res. 2012;61(6):563–569. doi: 10.1007/s00011-012-0445-7
   PubMed Web of Science ®Google Scholar
• Hagio T, Kishikawa K, Kawabata K, et al. Inhibition of neutrophil elastase reduces lung injury and bacterial count in hamsters. Pulm Pharmacol Ther. 2008;21(6):884–891. doi: 10.1016/j.pupt.2008.10.002
   PubMed Web of Science ®Google Scholar
• Lee JM, Yeo CD, Lee HY, et al. Inhibition of neutrophil elastase contributes to attenuation of lipopolysaccharide-induced acute lung injury during neutropenia recovery in mice. J Anesth. 2017;31(3):397–404. doi: 10.1007/s00540-017-2311-9
   PubMed Web of Science ®Google Scholar
• Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol. 2008;8(5):327–336. doi: 10.1038/nri2303
   PubMed Web of Science ®Google Scholar
• Stevens T, Ekholm K, Gränse M, et al. AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase. J Pharmacol Exp Ther. 2011;339(1):313–320. doi: 10.1124/jpet.111.182139
   PubMed Web of Science ®Google Scholar
• Li H, Zhou X, Tan H, et al. Neutrophil extracellular traps contribute to the pathogenesis of acid-aspiration-induced ALI/ARDS. Oncotarget. 2017;9(2):1772–1784. doi: 10.18632/oncotarget.22744
   PubMedGoogle Scholar
• von Nussbaum F, Li VM, Allerheiligen S, et al. Freezing the bioactive conformation to boost potency: the identification of BAY 85-8501, a selective and potent inhibitor of human neutrophil elastase for pulmonary diseases. ChemMedchem. 2015;10(7):1163–1173. doi: 10.1002/cmdc.201500131
   PubMed Web of Science ®Google Scholar
• Carnini C, Brogin G, Patacchini R, et al. CHF6333: pharmacological and pharmacokinetic characterization of a novel potent inhaled inhibitor of neutrophil elastase. Am J Respir Crit Care Med. 2017;195:A4420.
   Web of Science ®Google Scholar
• Sellier Kessler O, Lemercier G, Schmitt M, et al. Effect of POL6014, a potent and selective inhaled neutrophil elastase inhibitor, in a rat model of lung neutrophil activation. Am J Respir Crit Care Med. 2018;197:A2988.
   Web of Science ®Google Scholar
• Lagente V, Guenon I, Morel I, et al. A novel protein epitope mimetic (PEM) neutrophil elastase (NE) inhibitor, POL6014, inhibits human NE-induced acute lung injury in mice. Am J Respir Crit Care Med. 2009;179:A5668.
   Web of Science ®Google Scholar
• Sakashita A, Nishimura Y, Nishiuma T, et al. Neutrophil elastase inhibitor (sivelestat) attenuates subsequent ventilator-induced lung injury in mice. Eur J Pharmacol. 2007;571(1):62–71. doi: 10.1016/j.ejphar.2007.05.053
   PubMed Web of Science ®Google Scholar
• Kim DH, Chung JH, Son BS, et al. Effect of a neutrophil elastase inhibitor on ventilator-induced lung injury in rats. J Thorac Dis. 2014;6(12):1681–1689. doi: 10.3978/j.issn.2072-1439.2014.11.10
   PubMed Web of Science ®Google Scholar
• Kinoshita M, Ono S, Mochizuki H. Neutrophils mediate acute lung injury in rabbits: role of neutrophil elastase. Eur Surg Res. 2000;32(6):337–346. doi: 10.1159/000052215
   PubMed Web of Science ®Google Scholar
• Okeke EB, Louttit C, Fry C, et al. Inhibition of neutrophil elastase prevents neutrophil extracellular trap formation and rescues mice from endotoxic shock. Biomaterials. 2020;238:119836. doi: 10.1016/j.biomaterials.2020.119836
   PubMed Web of Science ®Google Scholar
• Tamakuma S, Shiba T, Hirasawa H, et al. A phase III clinical study of neutrophil elastase inhibitor ONO–5046*Na in SIRS patients. Rinsho Iyaku. 1998;14:289–318. (in Japanese).
   Google Scholar
• Okayama N, Kakihana Y, Setoguchi D, et al. Clinical effects of a neutrophil elastase inhibitor, sivelestat, in patients with acute respiratory distress syndrome. J Anesth. 2006;20(1):6–10. doi: 10.1007/s00540-005-0362-9
   PubMedGoogle Scholar
• Tamakuma S, Ogawa M, Aikawa N, et al. Relationship between neutrophil elastase and acute lung injury in humans. Pulm Pharmacol Ther. 2004;17(5):271–279. doi: 10.1016/j.pupt.2004.05.003
   PubMed Web of Science ®Google Scholar
• Aikawa N, Ishizaka A, Hirasawa H, et al. Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study. Pulm Pharmacol Ther. 2011;24(5):549–554. doi: 10.1016/j.pupt.2011.03.001
   PubMed Web of Science ®Google Scholar
• Kido T, Muramatsu K, Yatera K, et al. Efficacy of early sivelestat administration on acute lung injury and acute respiratory distress syndrome. Respirology. 2017;22(4):708–713. doi: 10.1111/resp.12969
   PubMed Web of Science ®Google Scholar
• Miyoshi S, Ito R, Katayama H, et al. Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients. Drug Des Devel Ther. 2014;8:1211–1219. doi: 10.2147/DDDT.S68030
   PubMed Web of Science ®Google Scholar
• Zeiher BG, Artigas A, Vincent JL, et al. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med. 2004;32(8):1695–1702. doi: 10.1097/01.CCM.0000133332.48386.85
   PubMed Web of Science ®Google Scholar
• Iwata K, Doi A, Ohji G, et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Intern Med. 2010;49(22):2423–2432. doi: 10.2169/internalmedicine.49.4010
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang M, Zhang H, et al. Sivelestat improves clinical outcomes and decreases ventilator-associated lung injury in children with acute respiratory distress syndrome: a retrospective cohort study. Transl Pediatr. 2022;11(10):1671–1681. doi: 10.21037/tp-22-441
   PubMed Web of Science ®Google Scholar
• Gao X, Zhang R, Lei Z, et al. Efficacy, safety, and pharmacoeconomics of sivelestat sodium in the treatment of septic acute respiratory distress syndrome: a retrospective cohort study. Ann Palliat Med. 2021;10(11):11910–11917. doi: 10.21037/apm-21-3164
   PubMed Web of Science ®Google Scholar
• Ding Q, Wang Y, Yang C, et al. Effect of sivelestat in the treatment of acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Intensive Care Res. 2023;3:1–10
   PubMedGoogle Scholar
• Miyoshi S, Hamada H, Ito R, et al. Usefulness of a selective neutrophil elastase inhibitor, sivelestat, in acute lung injury patients with sepsis. Drug Des Devel Ther. 2013;7:305–316. doi: 10.2147/DDDT.S42004
   PubMed Web of Science ®Google Scholar
• Ozawa T, Mihara K, Yasuno N. Predictors of the therapeutic effect of sivelestat in patients with acute lung injury associated with systemic inflammatory response syndrome. J Pharm Health Care Sci. 2016;2(1):19. doi: 10.1186/s40780-016-0051-x
   PubMedGoogle Scholar
• Mohamed MMA, El-Shimy IA, Hadi MA. Neutrophil elastase inhibitors: a potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications? Crit Care. 2020;24(1):311. doi: 10.1186/s13054-020-03023-0
   PubMed Web of Science ®Google Scholar
• Aikawa N, Kawasaki Y. Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome. Ther Clin Risk Manag. 2014;10:621–629. doi: 10.2147/TCRM.S65066
   PubMed Web of Science ®Google Scholar
• Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 Pt 1):818–824. doi: 10.1164/ajrccm.149.3.7509706
   PubMed Web of Science ®Google Scholar
• Zemans RL. Chapter 10 - acute respiratory distress syndrome. In: Sidhaye V Koval M, editors. Lung epithelial biology in the pathogenesis of pulmonary disease. Academic Press; 2017. p. 185–209. doi: 10.1016/B978-0-12-803809-3.00010-5
   Google Scholar
• Zemans RL, Briones N, Campbell M, et al. Neutrophil transmigration triggers repair of the lung epithelium via beta-catenin signaling. Proc Natl Acad Sci U S A. 2011;108(38):15990–15995. doi: 10.1073/pnas.1110144108
   PubMed Web of Science ®Google Scholar
• Hirche TO, Atkinson JJ, Bahr S, et al. Deficiency in neutrophil elastase does not impair neutrophil recruitment to inflamed sites. Am J Respir Cell Mol Biol. 2004;30(4):576–584. doi: 10.1165/rcmb.2003-0253OC
   PubMed Web of Science ®Google Scholar
• Tarhini M, Fessi H, Greige-Gerges H, et al. A potential new strategy for using elastase and its inhibitor as therapeutic agents. J Transl Sci. 2018;6:1–8.
   Google Scholar
• Sinha P, Calfee CS. Phenotypes in acute respiratory distress syndrome: moving towards precision medicine. Curr Opin Crit Care. 2019;25(1):12–20. doi: 10.1097/MCC.0000000000000571
   PubMed Web of Science ®Google Scholar
• Silva PL, Pelosi P, Rocco PRM. Personalized pharmacological therapy for ARDS: a light at the end of the tunnel. Expert Opin Investig Drugs. 2020;29(1):49–61. doi: 10.1080/13543784.2020.1699531
   PubMed Web of Science ®Google Scholar
• Wick KD, Aggarwal NR, Curley MAQ, et al. Opportunities for improved clinical trial designs in acute respiratory distress syndrome. Lancet Respir Med. 2022;10(9):916–924. doi: 10.1016/S2213-2600(22)00294-6
   PubMed Web of Science ®Google Scholar
• Grasselli G, CS C, Camporota L, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive care Med. 2023;49(7):727–759. doi: 10.1007/s00134-023-07050-7
   PubMed Web of Science ®Google Scholar